CTI submits expanded PIP to EMEA throughout pixantrone MAA against relapsed or refractory, disputatious NHL
Cubicle Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has submitted an expanded Pediatric Exploration Propose ("PIP") to the European Medicines Medium ("EMEA"), as as for of the proceeding on its resignation after a Marketing Authorization Use ("MAA") exchange for pixantrone in the E.U. destined for the treatment of relapsed or refractory, belligerent non-Hodgkin’s lymphoma (NHL). CTI intends to information the MAA later this year. The pediatric program wish burn the midnight oil pixantrone in pediatric patients ancient 6 months to 18 years with the purpose of determining the comparative cover and effectiveness of pixantrone compared to doxorubicin in pediatric lymphoid cancers.
CTI submitted the model PIP in September 2009. In April 2010, the EMEA Pediatric Body (the "PDCO") recommended CTI widen the PIP because of pixantrone’s dormant, but unproven, clinical advance to children in reducing long-term cardiotoxicity associated with la mode curative therapies. The guidance from the PDCO came following discussions with CTI to the preclinical and clinical pixantrone details, including PIX301, and the yearning to research the passive benefits pixantrone may come forward to children with hematologic cancer.
"Our discussions with the pediatric experts on the PDCO indicated that they come with our doctrine that the lack for the benefit of a less toxic, more efficient anthracycline-like instrument is important, not sole in lymphoma, but potentially in other tumors. We were in seventh heaven to fit their suggestions and suffer with adjusted the PIP in conformity," said Jack Vocalist, Chief Medical Public official of CTI. "Filing the updated PIP puts us identical remain alert closer to completing the MAA concession activity, and moves us toward our objective of making pixantrone nearby to right patients."
DOCUMENTATION Stall Therapeutics, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
